Article Series Commentary: Predicting PsA Progression, Managing Comorbidities, and Evaluating New Therapies, December 2024 Guselkumab Improves Disease Activity Across Multiple Domains in TNFi-IR PsA Apremilast Reduces MRI-Detected Inflammation in Joints and Entheses in PsA Deucravacitinib Yields Higher Minimal Disease Activity Response Than Placebo in PsA Musculoskeletal Ultrasound Predicts Treatment Response in PsA Risk Factors for Chronic Kidney Disease in PsA Identifying Predictors of Psoriatic Arthritis Progression in Patients with Arthralgia Depressive Symptoms Lower the Likelihood of Remission in PsA Real-World Study Shows Severity of Psoriasis Linked to Enthesitis in PsA Predictors of Treatment Response to b/tsDMARDs in PsA Guselkumab Lowers Serum Biomarker Levels and Improves Disease Activity in Biologic-Naive PsA Patients